Objective: We sought to characterize the treatment, as well as define the long-term outcomes, of patients with recurrent neuroendocrine liver metastasis (NELM).
worldwide. 1 The vast majority of patients with GEP-NET are diagnosed with either locally advanced or metastatic disease. In fact, while the natural history of many GEP-NET can be indolent, up to 60-90% of patients develop liver metastasis during the course of their disease. 2 The presence of neuroendocrine liver metastases (NELM)
can adversely impact patient quality of life via hormone secretion, as well as be associated with worse long-term outcomes. 3 Specifically, the 5-year overall survival (OS) of patients with NELM ranges from 13% to 54% versus 75% to 99% for patients with non-metastatic NET. [4] [5] [6] As such, treatment of NELM plays a central role in the management of patients with NET. 7 While management strategies for NELM include non-surgical approaches such as intra-arterial (IAT) or systemic targeted agents, [8] [9] [10] [11] [12] [13] [14] as well as octreotide and tyrosine kinases inhibitors, [11] [12] [13] surgery offers the best potential for cure. 6, 15, 16 Surgical resection of NELM has been associated with 5-year OS ranging from 61% to 76% and 10-year survival of 35% to 51%. 17, 18 Our group had previously reported that statistical cure following resection of NELM was 44% within 5.1 years after surgery. 19 These data suggest, however, that many patients experience recurrence. In particular, intrahepatic disease progression or recurrence has been reported to be as high as 70-90% within 5 years, depending on initial NELM tumor burden. 14, 18 The preferred management of patients with recurrent NELM following an initial surgical resection remains controversial. Several studies have reported on the safety and efficacy of repeat surgery in the treatment of colorectal liver metastasis, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma. [20] [21] [22] [23] Data on repeat surgical management of recurrent NELM are lacking, however. As such, the objective of the current study was to define the incidence and pattern of recurrent NELM following initial surgical resection. In addition, we sought to characterize the treatment of recurrent NELM and define treatment-specific long-term outcomes. Patients with a pancreatic or gastrointestinal primary NET had a higher incidence of recurrence (pancreatic NET: n = 96; 66.2% and gastrointestinal NET: n = 105; 68.4%) versus patients who had a primary NET from a non-pancreatic or gastrointestinal origin (other NET: n = 7, 30.4%; Table 1 ). In addition, patients with a primary pancreatic NET had higher risk of a late recurrence (n = 30, 20.7%) compared with either patients who had gastrointestinal NET (n = 24, 15.8%) or a primary NET from another origin (n = 2, 8.7%) (P < 0.05). Tumor grade was also associated with the incidence of recurrence (well-differentiated: n = 69, 51.5% vs moderately differentiated: n = 42, 65.6% vs poorly differentiated: n = 38, 77.5%) (P = 0.006). Other factors associated with recurrence included lymph node status (N0: n = 55, 39.8% vs N1: n = 126, 83.5%), (Table 1) . For example, patients who had an R0
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versus R1 margin had a comparable incidence of early recurrence (R0, n = 89, 42.4%; R1, n = 46, 58.2%), while R1 patients had almost a twofold increase incidence of late recurrence (R0, n = 27, 12.9%; R1, n = 18, 22.9%) (P < 0.001). The incidence of both early (<3 years) and late (≥3 years) recurrence was nearly double among patients with a non-functional NET (early: n = 98, 61.3%; late: n = 36, 22.5%) compared with patients who had a functional NET (early: n = 37, 38.5%; late: n = 12, 12.5%) (P < 0.001). In addition, when stratified by extent of liver disease, the incidence of recurrence was double in the early time period (<50%, n = 16, 23.9% vs ≥50%, n = 118, 52.4%) and increased to almost fourfold in the late time period (<50%, n = 3, 4.5% vs. ≥50%, n = 45, 20.0%) (P < 0.001).
| Site of recurrence
Data were available on the specific site of recurrence for 169 out of the 209 patients who had a recurrence. Among these 169 patients, the site of recurrence was intrahepatic only (n = 111, 65.7%), extrahepatic only (n = 19, 11.2%), or intra-and extra-hepatic (n = 39, 23.1%) ( Table 2) .
Several factors were associated with the site of recurrence ( Fig. 1 and Table 2 ). Specifically, patients who had an R1 resection were more likely to experience an intrahepatic only recurrence (n = 36, 50.8%) compared with patients who had an R0 resection (n = 66, 32.9%) (P = 0.001). In contrast, while patients with well-(n = 39, 31.9%), moderately-(n = 26, 45.6%), or poorly differentiated (n = 18, 40.0%) tumors had a similar incidence of intrahepatic recurrence, the incidence of extrahepatic only and combined intra-and extra-hepatic recurrence were markedly higher among patients with a poorly differentiated tumor (extrahepatic only: well, n = 4, 3.3% vs moderate, n = 1, 1.8%; vs poorly, n = 3, 6.7%; combined intra-and extra-hepatic recurrence: well, n = 14, 11.5% vs moderate, n = 8, 14.0% vs poorly, n = 13, 28.9%) (both P < 0.05). Extrahepatic recurrence was also much more common among patients with pancreatic (n = 11, 9.2%) and other non-GI NET (n = 2, 9.1%) compared with gastrointestinal NET (n = 6,
4.4%) (P = 0.005). Perhaps not surprisingly, patients who presented
with extrahepatic disease at initial diagnosis were more likely to recur with either extrahepatic disease only or combined intra-and extrahepatic disease (combined intra-and extra-hepatic recurrence:
extrahepatic disease at initial diagnosis, n = 8, 33.3% vs no-extrahepatic disease at initial diagnosis, n = 31, 12.0%; extrahepatic only: extrahepatic disease at initial diagnosis, n = 7, 29.2% vs no-extrahepatic disease at initial diagnosis, n = 12, 4.7%) (P < 0.001).
Of note, site of recurrence was associated with time of recurrence.
Specifically, most early recurrences within the first 3 years after surgery were either intrahepatic only (n = 88, 79.3%) or combined intra-and extra-hepatic recurrences (n = 31, 79.5%), while late recurrences after 3 years were more often extrahepatic only (n = 9, Compared with intrahepatic only recurrence, extrahepatic only and combined intra-and extra-hepatic recurrence were associated with a worse long-term outcome (10-year OS: intrahepatic only, 42.5%, 95%
CI, 24.9-59.0 vs extrahepatic only, 0% and combined intra-and extrahepatic, 21.5%, 95%CI, 5.3-44.0) ( Fig. 2 ; P < 0.001).
| Treatment of recurrence and long-term outcomes
Among the 137 patients who had information available on the treatment of recurrence, most patients were treated with repeat surgery (n = 49, 36.6%), while 34 (23.5%) patients received a somatostatin analogue, 27 (18.6%) systemic cytotoxic chemotherapy, and 27 (21.4%) patients had IAT. Patients with intrahepatic only recurrence were treated more often with repeat surgery (n = 39, 43.8%), while patients with intra-and extra-hepatic recurrence were more frequently treated with somatostatin analogues (n = 14, 43.8%) and chemotherapy (n = 12, 37.5%; P < 0.001). Of note, late recurrence was treated more often with repeat surgical resection (n = 9, 40.9%) or with somatostatin analogues (n = 9, 40.9%) than with systemic chemotherapy (n = 3, 16.6%) and IAT (n = 1, 4.6%). In comparison, systemic chemotherapy (n = 24, 23.1%) and IAT (n = 24, 23.1%) were employed with similar frequencies as somatostatin analogues (n = 25,
Histograms representing the incidence of (A) margin status, (B) grade of tumor differentiation, (C) location of primary NET, (D) extrahepatic disease at diagnosis, and (E) timing of recurrence among the different types of recurrence 24.0%) and repeat surgical resection (n = 31, 29.8%) for the treatment of early recurrence (Table 3 ; P = 0.08).
Following treatment of recurrent disease, 10-year OS among patients who underwent repeat surgery and intra-arterial treatments was 60.3% (95%CI, 34.1-78.8) and 52.0% (95%CI, 30.6-69.9), respectively. In contrast, patients who received somatostatin analogue (45.9% 95%CI, 22.3-66.9) or systemic chemotherapy (0%) had a shorter long-term survival ( Fig. 3 ; P = 0.001). (Table 2) . Perhaps not surprisingly, pattern of recurrence seemed to impact long-term outcomes (Fig. 2) 28 In particular, the combination of surgical resection with ablation may provide a chance for tumor eradication among patients with a large tumor burden or with recurrent NELM. 29, 30 In one study by Mayo et al that reported on 339 patients who underwent surgical management for NELM, the extent of 
| DISCUSSION
Variable N (%) N (%) N (%) N (%)
Pvalue
Treatment of recurrence S o m a t o s t a t i n analogous
Chemotherapy IAT Surgery N = 34 n = 27 n = 27 n = 49 hepatic resection among patients who underwent a repeat operation progressively diminished while ablation was used with increased frequency. 17 Collectively, data from previous reports as well as the current study, suggest that surgery, including with resection alone or with resection plus ablation should be considered for patients with recurrent disease-especially those with limited disease. For patients with more extensive disease, IAT may be a good option as this therapeutic approach was associated with a good long-term 10-year OS of over 50%.
This study has several limitations that should be considered when interpreting the results. First, the retrospective design of the study likely resulted in some confounding and selection/detection biases. In addition, because data were collected from multiple international centers, there was possible heterogeneity with the selection criteria and treatment approach for recurrent NELM disease. The inclusion of data from multiple centers does, however, increase the generalization of the findings. Finally, despite a large overall sample size, the relatively low number of patients with information on recurrence limited some of the subset analyses.
In conclusion, recurrence after curative intent surgery for NELM was common, occurring in three fourth of patients. Intrahepatic recurrence was the most common pattern of recurrence, although extrahepatic recurrence was also frequent. Pattern of recurrence was associated with specific clinical factors and impacted overall survival. When patients recur with NELM following initial surgical resection, therapy needs to be tailored with repeat liver resection considered when feasible as it may offer a reasonable long-term survival.
